41838-39-5

Usage

Uses

Used in Pharmaceutical Research and Development:
1,2,3,4-Tetrahydropyrazino[1,2-a]indole methanesulfonate is used as a potential drug candidate in pharmaceutical research and development for its possible therapeutic applications. Its unique chemical structure may offer novel pharmacological properties that could be beneficial in the treatment of various conditions, although further research is required to fully understand and validate its potential uses.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1,2,3,4-Tetrahydropyrazino[1,2-a]indole methanesulfonate is used for the exploration of its chemical and biological properties. Its synthesis and modification can provide insights into the development of new drugs with improved efficacy and safety profiles. 1,2,3,4-Tetrahydropyrazino[1,2-a]indole methanesulfonate's structure may also serve as a starting point for the design of new pharmaceutical agents targeting specific diseases or conditions.

InChI:InChI=1/C11H12N2/c1-2-4-11-9(3-1)7-10-8-12-5-6-13(10)11/h1-4,7,12H,5-6,8H2

Upstream product

• 3770-50-1 2-carbethoxyindole 
• 152193-85-6 4-oxo-1,2,3,4-tetrahydropyrazino<1,2-a>indole 
• 16732-70-0 ethyl 5-bromoindolecarboxylate 
• 126718-04-5 1-(cyanomethyl)indole-2-carboxylic acid ethyl ester 

Downstream Products

• 743466-41-3 benzyl 3,4-dihydropyrazino[1,2-a]indole-2(1H)-carboxylate 
• 1456735-52-6 [2-amino-4-((1,2,3,4-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)methyl)-thiophen-3-yl]-(4-chlorophenyl)methanone 
• 1456735-22-0 2-[3-(4-chlorobenzoyl)-4-(1,2,3,4-tetrahydro-1H-pyrazino[1,2-a]indol-2-ylmethyl)-thiophen-2-yl]-isoindole-1,3-dione 
• 1456734-83-0 2-[5-bromo-3-(4-chlorobenzoyl)-4-(1,2,3,4-tetrahydro-1H-pyrazino[1,2-a]indol-2-ylmethyl)-thiophen-2-yl]-isoindole-1,3-dione 

Relevant academic research and scientific papers

hERG Optimization of Benzofuro?Pyridine and Pyrazino?Indole Derivatives as MCHR1 Antagonists

Obesity is a global epidemic associated with multiple severe diseases. Several pharmacotherapies have been investigated including the antagonists of melanin concentrating hormone receptor 1 (MCHR1). The design, synthesis, and biological studies of novel MCHR1 antagonists based on benzofuro?pyridine and pyrazino?indole scaffold was performed. We confirmed that fine-tuning lipophilicity and basic pKa by modifying the benzyl group and introducing different substituents on the aliphatic nitrogen sidechain decreases both hERG inhibition and metabolic clearance. We have succeeded to develop excellent in vitro parameters in the case of compounds 17 (4-[(5-chloropyridin-2-yl)methoxy]-1-[4-(2-hydroxyethyl)-8-oxa-4-azatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraen-11-yl]-1,2-dihydropyridin-2-one monohydrochloride) and 23 g (4-[(5-chloropyridin-2-yl)methoxy]-1-(1,2,3,4-tetrahydropyrazino[1,2-a]indol-8-yl)pyridin-2(1H)-one monohydrochloride), which can be considered as valuable tools for further pharmacological investigation.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS

The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.

PHENYL mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands

Two novel series of melatonin-derived compounds have been synthesized and pharmacologically evaluated at the MT1 and MT2 subtypes of melatonin receptors. Compounds 12b-c are non-selective high-affinity MT1 and MT2/su

Evaluation of isotryptamine derivatives at 5-HT2 serotonin receptors

On the basis that meta-chlorophenylpiperazine (mCPP; 1) is a nonselective 5-HT2C agonist, that benz-fused tryptamines (e.g., 5) display enhanced 5-HT2 affinity, and that certain isotryptamines 3 reportedly bind with enhanced affinity and selectivity at 5-HT2C receptors, we prepared and examined a series of isotryptamine-related analogues as potentially selective 5-HT2C agonists. None of the compounds displayed selectivity for 5-HT2C versus 5-HT2A receptors. Detailed re-examination of a compound previously reported to display 100-fold 5-HT2C selectivity [i.e., S(+)-5,6-difluoro-α-methylisotryptamine] revealed that its selectivity versus 5-HT2A receptors was, at best, only 10-fold.